Healthcare Leaders Hub

🏠Home 📰News 📝Blog 🎬Videos Advertise Login

Your trusted source for pharmaceutical news, expert insights, and healthcare innovation.

💼𝕏 👥▶️

Content

📰News
📝Blog
🎬Videos

Company

🏠Home
🏢About Us
📧Contact

© 2026 PharmaVoice. All rights reserved. Empowering healthcare leaders.

Privacy Policy•Terms of Service

Novo targets blockbuster-heavy 2030 but share slump signals unease | PharmaVoice

Pharma Tech

Novo targets blockbuster-heavy 2030 but share slump signals unease

Sep 22, 2026, 10:59 AM

Read Full Article → Novo targets blockbuster-heavy 2030 but share slump signals unease

Novo targets blockbuster-heavy 2030 but share slump signals unease

Translate article text

Choose a language and wait for the translated text.

Novo is shaping a future beyond its Wegovy franchise as CEO Maziar Mike Doustdar looks to turn the drugmaker’s fortunes around.